- Home
- HSHP vs OLMA Comparison
HSHP vs OLMA Comparison
Compare HSHP & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- OLMA
- Stock Information
- Founded
- HSHP 2021
- OLMA 2006
- Country
- HSHP Bermuda
- OLMA United States
- Employees
- HSHP N/A
- OLMA N/A
- Industry
- HSHP
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- OLMA Health Care
- Exchange
- HSHP Nasdaq
- OLMA Nasdaq
- Market Cap
- HSHP 268.6M
- OLMA 299.7M
- IPO Year
- HSHP 2023
- OLMA 2020
- Fundamental
- Price
- HSHP $7.17
- OLMA $4.71
- Analyst Decision
- HSHP
- OLMA Strong Buy
- Analyst Count
- HSHP 0
- OLMA 4
- Target Price
- HSHP N/A
- OLMA $24.50
- AVG Volume (30 Days)
- HSHP 165.3K
- OLMA 572.4K
- Earning Date
- HSHP 08-20-2025
- OLMA 08-05-2025
- Dividend Yield
- HSHP 6.14%
- OLMA N/A
- EPS Growth
- HSHP 185.76
- OLMA N/A
- EPS
- HSHP 0.28
- OLMA N/A
- Revenue
- HSHP $121,972,000.00
- OLMA N/A
- Revenue This Year
- HSHP $11.22
- OLMA N/A
- Revenue Next Year
- HSHP $25.90
- OLMA N/A
- P/E Ratio
- HSHP $26.72
- OLMA N/A
- Revenue Growth
- HSHP 107.17
- OLMA N/A
- 52 Week Low
- HSHP $4.29
- OLMA $2.86
- 52 Week High
- HSHP $8.74
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- HSHP 66.19
- OLMA 53.79
- Support Level
- HSHP $6.67
- OLMA $4.40
- Resistance Level
- HSHP $7.39
- OLMA $4.76
- Average True Range (ATR)
- HSHP 0.21
- OLMA 0.28
- MACD
- HSHP 0.06
- OLMA 0.00
- Stochastic Oscillator
- HSHP 80.52
- OLMA 53.12
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.